🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer

Recruitingn/aAges 18 Years - anyAllOslo University Hospital
NCT06944587 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

NORPACT-3 is a nationwide, Norwegian single arm prospective study that evaluates the resectability rates and survival in patients with borderline resectable and locally advanced pancreatic cancer who received primary chemotherapy. Eligible patients are treated with primary chemotherapy possibly followed by surgical exploration and resection. All Norwegian centres performing pancreatic surgery have agreed to collaborate in this trial. The assignment of the medical intervention is not at the discretion of the investigator, but follow the national Norwegian guidelines regarding diagnostic work up, oncological and surgical treatment and follow up. The primary aim is a national resection rate of 50% in BRPC and 15% in LAPC in patients initiating primary chemotherapy, with adequate overall survival and morbidity/mortality (after resection median overall survival of 24 months, 1 year survival 8

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Borderline resectable or locally advanced adenocarcinoma of the pancreas (NCCN, version 2, 2021) (Appendix 3) * Nx, M0 (UICC 8th version, 2016) * Cytological or histological confirmation of adenocarcinoma * Age \>18 year * Considered able to receive primary chemotherapy and possible surgery * Written informed consent Exclusion Criteria: * Co-morbidity or performance status precluding primary chemotherapy * Co-morbidity or performance status precluding pancreatectomy * Female patients in child-bearing age not using adequate contraception, pregnant or lactating women * Mental or physical disorders that could interfere with treatment of with the provision of informed consent * Any reason why, in the opinion of the investigator, the patient should not participate
💊

What it tests

  • Chemotherapy
  • Radiology
  • Pancreatectomy
  • Endoscopy
📍

Where

5 sites
Haukeland University Hospital
Bergen, Norway
Stavanger University Hospital
Stavanger, Norway
University Hospital of North Norway
Tromsø, Norway
St. Olavs Hospital, Trondheim University Hospital
Trondheim, Norway
Oslo University Hospital
Oslo, Norway
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy